首页> 外文期刊>American Journal of Laboratory Medicine >Poor Prognostic Factors in Sickle Cell Disease Patients Infected with Covid-19 - Review of Literatures
【24h】

Poor Prognostic Factors in Sickle Cell Disease Patients Infected with Covid-19 - Review of Literatures

机译:感染Covid-19感染患者的镰状细胞病患者的预后因素差 - 文献综述

获取原文
           

摘要

Sickle cell disease (SCD) is the co-inheritance of HbS with other abnormal haemoglobin. COVID-19 is a severe acute respiratory distress syndrome caused by coronavirus 2 infections. The immunosuppression and chronic inflammatory states in patients with SCD predispose them to severe form of COVID-19. The few case studies on sickle cell disease patients infected with COVID-19 mostly discuss the pattern of clinical presentations and laboratory changes in patients with SCD infected with COVID-19. This review of literature assesses the prognostic indicators in sickle cell disease patients infected with COVID 19 in three major case series. Some presenting symptoms and signs, presence of comorbidities and certain laboratory parameters were compared with poor outcome of patients. Poor clinical outcomes of patients in this review included: 1. Duration of admission of 10 days, 2. A week or more of intensive care unit admission, 3. Death of patient despite intervention while on admission, and 4. Deterioration in the presenting comorbid clinical condition. The presenting symptoms and signs, presence of comorbidities and certain laboratory parameters associated with these poor clinical outcomes were considered as poor prognostic factors. The presence of comorbidities, markedly elevated pro-inflammatory markers such as leukocytosis, IL-6, C-reactive proteins, marked elevated D-Dimer and high serum creatinine are poor prognostic factors in sickle cell disease patients with COVID-19 infection.
机译:镰状细胞疾病(SCD)是HBS与其他异常血红蛋白的共遗传性。 Covid-19是由冠状病毒2感染引起的严重急性呼吸窘迫综合征。 SCD患者的免疫抑制和慢性炎症态使其成为Covid-19的严重形式。少量关于感染Covid-19感染的镰状细胞病患者的案例研究主要讨论SCD感染Covid-19患者临床介绍和实验室变化的模式。该文献综述评估了在三个主要案例系列中感染Covid 19感染的镰状细胞病患者的预后指标。一些呈现症状和标志,具有较差的患者的结果和某些实验室参数。本综述临床结果不佳:1。入院持续时间10天,2.一周或更长时间的重症监护单位入场,3.患者死亡尽管入院时干预,而且患者在本阶段劣化临床状况。呈现症状和体征,具有与这些较差的临床结果相关的合并症和某些实验室参数被认为是差的预后因素。合并症的存在明显升高的促炎标记,例如白细胞增多症,IL-6,C反应蛋白,标记升高的D-二聚体和高血清肌酐在镰状细胞病患者患者的镰状细胞病患者的预后因素差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号